Table 1 Analysis of % decrease of liver lipid, galectin-3 (gal-3), and type I collage α1 chain (col1a1). Decrease was analyzed based on levels of the respective NASH vehicle group for terminal biopsy, whole liver, left lateral, medial and right lateral lobe. Data expressed as mean percentage (n = 10–12)
From: Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH
Analysis mass (mg) | Group | Biopsy % decrease | Whole liver % decrease | Left lateral lobe % decrease | Medial lobe % decrease | Right lateral lobe % decrease |
|---|---|---|---|---|---|---|
Liver lipid | INT-767 | 58 | 49 | 50 | 47 | 55 |
Liraglutide | 62 | 59 | 57 | 65 | 51 | |
Elafibranor | 58 | 54 | 57 | 52 | 53 | |
Gal-3 | INT-767 | 54 | 58 | 51 | 62 | 58 |
Liraglutide | 47 | 46 | 41 | 52 | 35 | |
Elafibranor | 38 | 46 | 48 | 45 | 45 | |
Col1a1 | INT-767 | 38 | 58 | 61 | 55 | 57 |
Liraglutide | 41 | 38 | 42 | 38 | 24 | |
Elafibranor | 11 | 26 | 24 | 29 | 25 |